Fig. 4

CLL-1 CAR-T cells eliminate human AML in xenograft models. a Schematic of the U937 xenograft model. NSG mice were injected via tail vein with 1 × 10⁶ U937-firefly luciferase (U937-ffLuc) on day 1. Bioluminescent imaging (BLI) was performed on day 7 to quantify engraftment and for randomization of treatment groups. CLL-1 CAR-T cells (1–1.5 × 10⁶), Mock T cells (1–1.5 × 10⁶), or PBS were injected iv on day 8 and day 12, and mice were followed with serial BLI. Quantification of BLI radiance was used as a surrogate measurement of AML burden. b BLI prior to T cell treatment (day 7), on day 15, and on day 29 following U937-ffLuc transplantation. c Bioluminescent signal for each treatment group over time. Data represent mean values of each group ± SD. Results represent pooled data from three separate experiments. d Kaplan-Meier analysis of survival. Log-rank (Mantel-Cox) tests were used to perform statistical analyses of survival between groups. Data were summarized from three independent experiments. e Representative flow cytometric analysis of peripheral blood 18 days after leukemia transplant. Percentage of human CD45⁺ CLL-1⁺ U937 cells is indicated. f Summary of leukemic cell engraftment in mouse peripheral blood 18 days after leukemia transplant. The percentage of human CD45⁺ CLL-1⁺ U937 cells is indicated. Each symbol indicates one mouse